Reasons and ways to reduce the severity of the acute phase reaction in the treatment of osteoporosis with intravenous bisphosphonates (literature review)

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Bisphosphonates (BPs) are the first-line treatment for osteoporosis and are prescribed to the majority of patients with this disease. However, worldwide concern among osteoporosis practitioners is the lack of initiation and adherence to this class of drugs. One of the reasons for this is the most common side effect that occurs when taking this group of drugs – acute phase reaction (APR), or influenza-like syndrome. The article presents the results of scientific studies and meta-analyses aimed at assessing the clinical characteristics of this side effect, its prevalence, as well as those factors that may influence the reduction of its frequency and severity. The data obtained during the studies must be taken into account in clinical practice when prescribing drugs of this group, which will help increase adherence to treatment and achieve a reduction in the number of osteoporotic fractures.

Full Text

Restricted Access

About the authors

K. Yu. Belova

Yaroslavl State Medical University

Author for correspondence.
Email: ksbelova@mail.ru
ORCID iD: 0000-0002-7856-1567

Dr. Sci. (Med.)

Russian Federation, Yaroslavl

O. B. Ershova

Yaroslavl State Medical University

Email: ksbelova@mail.ru
ORCID iD: 0000-0001-7167-2187
Russian Federation, Yaroslavl

A. V. Nazarova

Yaroslavl State Medical University; N.V. Solovyov Clinical Hospital of Emergency Medical Care

Email: ksbelova@mail.ru
ORCID iD: 0000-0003-3198-5829
Russian Federation, Yaroslavl; Yaroslavl

Z. A. Matyakubova

Yaroslavl State Medical University; Clinical Hospital No. 2

Email: ksbelova@mail.ru
ORCID iD: 0009-0006-9910-5110
Russian Federation, Yaroslavl; Yaroslavl

References

  1. Лесняк О.М. Аудит состояния проблемы остеопороза в Российской Федерации. Профилактическая медицина. 2011;14(2):7–10. [Lesnyak O.M. Audit of the state of the problem of osteoporosis in the Russian Federation. Profilakticheskaya meditsina. 2011;14(2):7–10. (In Russ.)].
  2. Lesnyak O., Ershova O., Belova K., et al. Epidemiology of fracture in the Russian Federation and the development of a FRAX model. Arch Osteoporos. 2012;7(1–2):67–73. doi: 10.1007/s11657-012-0082-3.
  3. Белая Ж.Е., Белова К.Ю., Бирюкова Е.В. и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Остеопороз и остеопатии. 2021;24(2):4–47. [Belaya Z.E., Belova K.Y., Biryukova E.V., et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and Bone Diseases. 2021;24(2):4–47. (In Russ.)]. doi: 10.14341/osteo129301.
  4. Khosla S., Shane E. A Crisis in the Treatment of Osteoporosis. J Bone Miner Res. 2016;31(8):1485–87. doi: 10.1002/jbmr.2888.
  5. Li C., Lu K., Shi Q., Gong Y.Q. Predicting the individualized risk of nonadherence to zoledronic acid among osteoporosis patients receiving the first infusion of zoledronic acid: development and validation of new predictive nomograms. Ther Adv Chronic Dis. 2022;30;13:20406223221114214. doi: 10.1177/20406223221114214.
  6. Reid I.R., Gamble G.D., Mesenbrink P., Lakatos P. and Black D.M. Characterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid. Clin Endocrinol Metab. 2010;95:4380–87. doi: 10.1210/jc.2010-0597.
  7. Dicuonzo G., Vincenzi B., Santini D., et al. Fever after zoledronic acid administration is due to increase in TNF-α and IL-6. J Interferon Cytokine Res. 2003; 23(11):649–54. doi: 10.1089/107999003322558782.
  8. Лесняк О.М., Аношенкова О.Н., Барбарин И.Н. и др. Результаты двухлетнего открытого многоцентрового наблюдательного исследования эффективности, безопасности, переносимости и влияния на качество жизни. Лечащий врач. 2018;3:9–18. [Lesnyak O.M., Anoshenkova O.N., Barbarin I.N., et al. Results of a two-year open multicenter observational study of effectiveness, safety, tolerability and impact on quality of life. Lechashchii vrach. 2018;3:9–18. (In Russ.)].
  9. Black D.M., Delmas P.D., Eastell R., et al. HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–22. doi: 10.1056/NEJMoa067312.
  10. Шафиева И.А., Булгакова С.В., Шафиева А.В. Оценка переносимости препаратов золедроновой кислоты для парентерального введения. Медицинский совет. 2022;(11):96–101. [Shafieva I.A., Bulgakova S.V., Shafieva A.V. ssessment of tolerability of zoledronic acid preparations for parenteral administration. Meditsinskii sovet. 2022;(11):96–101. (In Russ.)]. doi: 10.21518/2079-701X-2022-16-11-96-101.
  11. Wark J.D., Bensen W., Recknor C., et al. Treatment with acetaminophen/ paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporos Int. 2012;23(2):503–12. doi: 10.1007/s00198-011-1563-8.
  12. Sieber P., Lardelli P., Kraenzlin C.A., et al. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice. Clin Drug Investig. 2013;33(2):117–22. doi: 10.1007/s40261-012-0041-1.
  13. Bock O., Boerst H., Thomasius F.E., et al. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact. 2007;7(2):144–48.
  14. Аnastasilakis A.D., Polyzos S.A., Makras P., et al. Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass. Bone. 2012;50(5):1130–34. doi: 10.1016/j.bone.2012.02.006.
  15. Popp A., Senn R., Curkovic I., et al. Factors associated with acute-phase response of bisphosphonate-naive or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate. Osteoporos Int. 2017;28(6):1995–2002. doi: 10.1007/s00198-017-3992-5.
  16. Billington E.O., Horne A., Gamble G.D., et al. Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial. Osteoporos Int. 2017;28:1867–74. doi: 10.1007/s00198-017-3960-0.
  17. Smrecnik M., Kavcic Trsinar Z., Kocjan T. Adrenal crisis after first infusion of zoledronic acid: a case report. Osteoporos Int. 2018;29(7):1675-78. doi: 10.1007/s00198-018-4508-7.
  18. Makras P., Anastasilakis A.D., Polyzos S.A., et al. No effect of rosuvastatin in the zoledronateinduced acute-phase response. Calcif Tissue Int. 2011;88(5): 402–8. doi: 10.1016/j.bonr.2021.101128.
  19. Srivastava T., Haney C.J., Alon U.S. Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion. J Bone Miner Res. 2009;24(2):334–37. doi: 10.1359/jbmr.081016.
  20. Thompson K., Keech F., McLernon D.J., Vinod K., et al. Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women. Bone. 2011;49(1):140–45. doi: 10.1016/j.bone.2010.10.177.
  21. Wang H., Hu Z.H., Chen L., Pan Y. Influence of history of oral bisphosphonates on the incidence rate of fever after intravenous injection of zoledronic acid in patients with osteoporosis. Beijing Da Xue Xue Bao Yi Xue Ban. 2016;48(4):680–82.
  22. Deng J.M., Cai D.M., Jie S.M., et al. Sequential Treatment Reduces the Acute Phases of Adverse Effect of Zoledronic Acid in First Time Users. Open Journal of Preventive Medicine. 2018;08(07):189–205. doi: 10.4236/ojpm.2018.87018.
  23. Chiara C., Watts N.B., De Santis M., et al. Acute phase reactions after zoledronic acid infusion: protective role of 25-hydroxyvitamin D and previos oral bisphosphonate therapy. Endocrine Practice. 2018;24(5):405–10. doi: 10.4158/EP161638.
  24. Lu K., Shi Q., Gong Y.Q., Li C. Association between vitamin D and zoledronate-induced acute-phase response fever risk in osteoporotic patients. Front Endocrinol (Lausanne). 2022;10;13:991913. doi: 10.3389/fendo.2022.991913.
  25. Bertoldo F, Pancheri S, Zenari S, et al. Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J Bone Miner Res. 2010;25(3):447–54. doi: 10.1359/jbmr.090819.
  26. Tsurukami H. Acute phase reaction following bisphosphonates. Clin Calcium. 2017; 27(2):213–23.
  27. Black D.M., Reid I.R., Napoli N., et al. The interaction of acute-phase reaction and efficacy for osteoporosis after zoledronic acid: HORIZON pivotal fracture trial J Bone Miner Res. 2021;37(1):21–8. doi: 10.1002/jbmr.4434.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. Pathogenesis of OFR formation with the use of BF [7]

Download (111KB)
Indexing metadata

Copyright (c) 2024 Bionika Media